Accelerating development of genetic therapies for muscular dystrophies
The aim of MAGIC is to accelerate the development of gene therapies and genome editing strategies for muscular dystrophies by creating advanced humanized muscle models and innovative gene therapy approaches, ultimately improving the lives of individuals affected by these debilitating diseases.
Key Objectives
- Creating accurate humanized muscle models.
- Developing precise gene therapies and genome editing strategies.
- Engineering disease-specific muscle-on-chip devices.
- Assessing safety and efficacy of novel gene therapies.
- Exploring gene editing strategies for neuromuscular disorders.
- Facilitating translation and exploitation of project outputs.
- Ensuring patient perspectives remain central to the research.
See how MAGIC is working to reach these key objectives
Latest News
MAGIC GA Meeting 2026 San Sebastián
MAGIC Horizon Project Holds Its 4th General Assembly in San Sebastián The MAGIC Horizon consortium successfully convened for its 4th General Assembly on 1–2 June 2026 in San Sebastián, Spain, kindly...
MAGIC Consortium welcomes new partners to strengthen technology development and exploitation activities
iMM has joined the MAGIC Project to advance biomedical research by enhancing muscle-on-chip technologies and the development of new disease models.
Rare Disease Day with the MAGIC team
Rare Disease Day is observed every year on 28 February. It was established and coordinated by EURORDIS in partnership with over 70 national alliance patient organisations to spotlight the 300...